NO20060641L - Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser - Google Patents

Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser

Info

Publication number
NO20060641L
NO20060641L NO20060641A NO20060641A NO20060641L NO 20060641 L NO20060641 L NO 20060641L NO 20060641 A NO20060641 A NO 20060641A NO 20060641 A NO20060641 A NO 20060641A NO 20060641 L NO20060641 L NO 20060641L
Authority
NO
Norway
Prior art keywords
formula
compounds
inhibitors
receptor tyrosine
tyrosine kinases
Prior art date
Application number
NO20060641A
Other languages
English (en)
Norwegian (no)
Inventor
Laurent Francois A Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060641L publication Critical patent/NO20060641L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
NO20060641A 2003-08-06 2006-02-09 Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser NO20060641L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318423.1A GB0318423D0 (en) 2003-08-06 2003-08-06 Chemical compounds
PCT/GB2004/003393 WO2005013998A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
NO20060641L true NO20060641L (no) 2006-05-03

Family

ID=27839733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060641A NO20060641L (no) 2003-08-06 2006-02-09 Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser

Country Status (14)

Country Link
US (1) US20070027145A1 (zh)
EP (1) EP1653965A1 (zh)
JP (1) JP2007501212A (zh)
KR (1) KR20060058781A (zh)
CN (1) CN1863534A (zh)
AU (1) AU2004262982A1 (zh)
BR (1) BRPI0413280A (zh)
CA (1) CA2534422A1 (zh)
GB (1) GB0318423D0 (zh)
IL (1) IL173483A0 (zh)
MX (1) MXPA06001394A (zh)
NO (1) NO20060641L (zh)
WO (1) WO2005013998A1 (zh)
ZA (1) ZA200601030B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
EA201290505A1 (ru) * 2009-12-15 2013-01-30 Ньюроп, Инк. Соединения для лечения неврологических расстройств
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN105330653A (zh) * 2014-08-11 2016-02-17 石药集团中奇制药技术（石家庄）有限公司 喹唑啉衍生物
US9854482B2 (en) * 2015-04-21 2017-12-26 International Business Machines Corporation Controlling a delivery of voice communications over a cellular data network or a wireless network based on user's profile
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN106565681B (zh) * 2016-11-10 2019-07-09 中国医学科学院放射医学研究所 含硝基咪唑基团的苯胺喹唑啉类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
IL125686A (en) * 1996-02-13 2002-11-10 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability
DE69709319T2 (de) * 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
IL142359A0 (en) * 1998-10-08 2002-03-10 Astrazeneca Ab Quinazoline derivatives
KR20080015482A (ko) * 1999-02-10 2008-02-19 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
US7173038B1 (en) * 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
AU779695B2 (en) * 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds

Also Published As

Publication number Publication date
EP1653965A1 (en) 2006-05-10
WO2005013998A1 (en) 2005-02-17
MXPA06001394A (es) 2006-05-19
ZA200601030B (en) 2007-05-30
BRPI0413280A (pt) 2006-10-10
CN1863534A (zh) 2006-11-15
US20070027145A1 (en) 2007-02-01
AU2004262982A1 (en) 2005-02-17
GB0318423D0 (en) 2003-09-10
IL173483A0 (en) 2006-06-11
CA2534422A1 (en) 2005-02-17
JP2007501212A (ja) 2007-01-25
KR20060058781A (ko) 2006-05-30

Similar Documents

Publication Publication Date Title
NO20060641L (no) Kinazolinderivater som inhibitorer av VEGF-reseptortyrosinkinaser
NO20060650L (no) Kinazolinderivater som angiogeneseinhibitorer
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
MA33540B1 (fr) Dérivés de la pyridine et de la pyrazine en tant que modulateurs de la protéine kinase
EA200300354A1 (ru) Хинолиноновые производные в качестве ингибиторов тирозинкиназы
BRPI0515499A (pt) derivados de piridina para a inibição de estearoil-coa-desaturase humana
UA99361C2 (uk) ТРИАЗИНИ ЯК ІНГІБІТОРИ PІ3-КІНАЗИ І mTOR
DK1678166T3 (da) Proteinkinaseinhibitorer
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
MXPA04004301A (es) Bencimidazoles sustituidos utiles como inhibidores de la proteina cinasa.
TNSN07022A1 (fr) Derives de pyridine
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
YU84603A (sh) Novi inhibitori tirozin kinaze
NO20070258L (no) Benzyltriazolonforbindelser som ikke-nukleoside revers transkriptase inhibitorer
NO20065320L (no) Imidazolderivater anvendt som tafiainhibitorer
PE20081393A1 (es) Derivados de quinolina como inhibidores de csf-1r
NO20076196L (no) Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander
DE60129934D1 (de) Verwendung von pdgf-rezeptor tyrosin kinase inhibitoren zur behandlung von diabetischer nephropathie
DE60002714D1 (de) Substituierte azaoxindolederivate
BRPI0409255A (pt) derivados de ácido 2-(8,9-dioxo-2,6-diazabi-ciclo(5.2.0)non-1(7)-en-2-il)alquil fosfÈnico e seu uso como antagonistas de receptores de d-asparto de -n-metila (nmda)
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20063865L (no) Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application